Current Trials

Name No. For Patients with Purpose
“XPORT” – ENGOT-EN20/GOG-3083/XPORT-EC-042 22-08

p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma.

When we say someone has p53 wildtype cancer, it means their guardian (p53) is working as it should. It’s like having a strong and reliable guardian who can keep an eye on things and prevent trouble (like stopping cells from growing out of control).

So, in simple terms, p53 wildtype cancer means the guardian in the body is doing its job properly, but still, cancer has somehow developed.

The purpose of this study is to evaluate the efficacy and safety of Selinexor as a maintenance treatment in patients with p53 wildtype endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumours version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomised in a 1:1 ratio to maintenance therapy with either Selinexor or placebo.


Name No. For Patients with Purpose
22-09 ADEPPT 22-09

Lung caner patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status[Cohort 1] or Elderly (≥70 years) [Cohort 2]

The purpose of the trial is to assess the clinical efficacy of adagrasib treatment in patients with KRASG12C-mutant NSCLC, in patients who are elderly (≥70 years) or those with poor performance status (ECOG PS=2).


Name No. For Patients with Purpose
22-15 PLAN 22-15

Advanced or locally advanced Non-Small Cell Lung Cancer

Purpose of this study is to evaluate whether plasma genotyping via an in-house next generation sequencing (NGS) panel, will identify actionable genomic alterations in patients with newly diagnosed advanced or locally advanced non-squamous NSCLC


Name No. For Patients with Purpose
22-23 NeoCOAST-2 22-23

Early-Stage (II to IIIA) Non-small Cell Lung Cancer

The purpose is to evaluate pathologic complete response in patients treated with Durvalumab with Oleclumab or Monalizumab. Also safety and tolerability of Durvalumab.


Name No. For Patients with Purpose
23-12 LATIFY 23-12

patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

The purpose of the study is to measure Overall Survival (OS). OS is defined as time from randomisation until the date of death due to any cause. The superiority of ceralasertib plus durvalumab combination therapy relative to docetaxel will be demonstrated by assessment of OS


Name No. For Patients with Purpose
AcceleRET-Lung 20-21

This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body.

AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC).


Name No. For Patients with Purpose
AFFIRM-AL 22-13

The target population for this study are Mayo Stage IV AL amyloid patients

This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients


Name No. For Patients with Purpose
Astellas 8951-CL-5201 CTRIAL-IE 18-44

Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment.

This study will also evaluate tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM, and health-related quality of life (HRQoL).


Name No. For Patients with Purpose
BRAND 23-11

Non-Small Cell Lung Cancer

The main purpose of this study is see if EBC(Exhaled Breath Condensate) can be used to check for biomarkers which are associated with a radiologic response to chemoimmunotherapy for patients with advanced NSCLC


Name No. For Patients with Purpose
BRUIN CLL-322 20-21-44

Previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.


Name No. For Patients with Purpose
CA057-001 CA057-001

Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment.

To determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment.

Name No. For Patients with Purpose
CA058-1019 CA058-1019

Relapsed or refractory multiple myeloma who have already had 2 to 3 lines of MM therapy, including a drug called lenalidomide and a drug from a class called anti-CD38 antibodies.

The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).


Name No. For Patients with Purpose
CompARE 17-14

intermediate and high-risk oropharyngeal
cancer

To examine the outcomes of alternative treatments aiming to improve overall survival time in intermediate and high-risk oropharyngeal cancer and to compare Quality of Life (QoL), toxicity outcomes and swallowing function of these alternative treatments


Name No. For Patients with Purpose
DASL HiCaP CTRIAL-IE 19-32

People aged 18 years or older with either very high-risk localised prostate cancer, or very high risk features with PSA persistence or rise within one year following radical prostatectomy, suitable for Radiotherapy.

Determine the effectiveness of adding Darolutamide to androgen deprivation therapy (ADT) and radiation therapy in either the primary definitive setting or very high risk postoperative setting.


Name No. For Patients with Purpose
DESTINY DS8201-A-U306   21-07

HER-2 positive metastatic and/or unresectable gastric or gasto-esophageal junction (GEJ) cancer

This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd), a HER-2 targeting antinbody drug, compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) cancer who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy.